Reversal of experimental pulmonary hypertension by PDGF inhibition

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2811-2821

  Schermuly, Ralph Theo ^a,b   Dony, Eva ^a   Ghofrani, Hossein Ardeschir ^a   Pullamsetti, Soni ^a   Savai, Rajkumar ^a   Roth, Markus ^a   Sydykov, Akylbek ^a   Lai, Ying Ju ^a   Weissmann, Norbert ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MONOCROTALINE; PLATELET DERIVED GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; COR PULMONALE; DRUG EFFECT; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; STIMULUS RESPONSE; TELEMETRY; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 26444540768     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24838     Document Type: Article

References (61)

1. Humbert, M., Sitbon, O., and Simonneau, G. 2004. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351:1425-1436.
2. Barst, R.J., et al. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334:296-302.
3. Olschewski, H., et al. 2002. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347:322-329.
4. Rubin, L.J., et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346:896-903.
5. Humbert, M., et al. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43:135-245.
6. Jones, P.L., Cowan, K.N., and Rabinovitch, M. 1997. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am. J. Pathol. 150:1349-1360.
7. Ushio-Fukai, M., et al. 2001. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21:489-495.
8. Xin, X., Johnson, A.D., Scott-Burden, T., Engler, D., and Casscells, W. 1994. The predominant form of fibroblast growth factor receptor expressed by proliferating human arterial smooth muscle cells in culture is type I. Biochem. Biophys. Res. Commun. 204:557-564.
9. Balasubramaniam, V., et al. 2003. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell Mol. Physiol. 284:L826-L833.
10. Yu, Y., et al. 2003. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am. J. Physiol. Cell Physiol. 284:C316-C330.
11. Heldin, C.H., and Westermark, B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79:1283-1316.
12. Bergsten, E., et al. 2001. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell Biol. 3:512-516.
13. LaRochelle, W.J., et al. 2001. PDGF-D, a new protease-activated growth factor. Nat. Cell Biol. 3:517-521.
14. Li, X., et al. 2000. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2:302-309.
15. Heldin, C.H., Ostman, A., and Ronnstrand, L. 1998. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta. 1378:F79-F113.
16. Rosenkranz, S., and Kazlauskas, A. 1999. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors. 16:201-216.
17. Humbert, M., et al. 1998. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 11:554-559.
18. Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. 2002. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:493-502.
19. Cohen, M.H., et al. 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8:935-942.
20. Dagher, R., et al. 2002. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8:3034-3038.
21. Olschewski, H., et al. 2002. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347:322-329.
22. Ghofrani, H.A., et al. 2002. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 360:895-900.
23. Ghofrani, H.A., et al. 2002. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136:515-522.
24. Ghofrani, H.A., et al. 2004. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann. Intern. Med. 141:169-177.
25. Zhao, L., et al. 2001. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 104:424-428.
26. Eddahibi, S., et al. 2000. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am. J. Respir. Crit. Care Med. 162:1493-1499.
27. Tanabe, Y., et al. 2000. Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol. Cell. Biochem. 215:103-113.
28. Jankov, R.P., et al. 2005. A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. 288:L1162-L1170.
29. Wensel, R., et al. 2002. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 106:319-324.
30. Cowan, K.N., et al. 2000. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6:698-702.
31. Nishimura, T., et al. 2002. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 166:1403-1408.
32. Abe, K., et al. 2004. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 94:385-393.
33. Schermuly, R.T., et al. 2004. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169:39-45.
34. Schermuly, R.T., et al. 2004. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94:1101-1108.
35. Jeffery, T.K., and Wanstall, J.C. 2001. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol. Ther. 92:1-20.
36. Rosenberg, H.C., and Rabinovitch, M. 1988. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am. J. Physiol. 255:H1484-H1491.
37. Okada, K., et al. 1997. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am. J. Pathol. 151:1019-1025.
38. Frisdal, E., et al. 2001. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur. Respir. J. 18:838-845.
39. Weissmann, N., et al. 2003. Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 284:H931-H938.
40. Chen, E.Y., Mazure, N.M., Cooper, J.A., and Giaccia, A.J. 2001. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 61:2429-2433.
41. Leppanen, O., et al. 2004. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation. 109:1140-1146.
42. Van, S.M., Kazlauskas, A., Schreiber, S.L., and Symes, K. 2005. Distinct effectors of platelet-derived growth factor receptor-alpha signaling are required for cell survival during embryogenesis. Proc. Natl. Acad. Sci. U. S. A. 102:8233-8238.
43. Vantler, M., Caglayan, E., Zimmermann, W.H., Baumer, A.T., and Rosenkranz, S. 2005. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3′-kinase is important. J. Biol. Chem. 280:14168-14176.
44. Datta, K., Bellacosa, A., Chan, T.O., and Tsichlis, P.N. 1996. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 271:30835-30839.
45. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H., and Downward, J. 1997. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16:2783-2793.
46. Chiorean, M.V., et al. 2004. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int. 24:687-695.
47. Dan, S., Naito, M., and Tsuruo, T. 1998. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5:710-715.
48. Cho, A., Graves, J., and Reidy, M.A. 2000. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20:2527-2532.
49. Laurent, M., et al. 2003. NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-alpha-dependent mechanism. FASEB J. 17:1919-1921.
50. Endo, H., Utani, A., and Shinkai, H. 2003. Activation of p38 MAPK suppresses matrix metalloproteinase-1 gene expression induced by platelet-derived growth factor. Arch. Dermatol. Res. 294:552-558.
51. Davis, R.J. 1993. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
52. Sanz-Gonzalez, S.M., Castro, C., Perez, P., and Andres, V. 2004. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression. Biochem. Biopbys. Res. Commun. 317:972-979.
53. Ishizawa, K., et al. 2004. Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem. Biophys. Res. Commun. 324:276-280.
54. Myllarniemi, M., et al. 1999. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther. 13:159-168.
55. Hu, Y., Bock, G., Wick, G., and Xu, Q. 1998. Activation of PDGF receptor alpha in vascular smooth muscle cells by mechanical stress. FASEB J. 12:1135-1142.
56. Resnick, N., et al. 1993. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element [erratum]. Proc. Natl. Acad. Sci. U. S. A. 90:7908.
57. Buchdunger, E., et al. 1995. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U. S. A. 92:2558-2562.
58. Buchdunger, E., et al. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:139-145.
59. Wilkinson Berka, J.L., et al. 2004. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am. J. Pathol. 164:1263-1273.
60. Rose, F., et al. 2002. Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J. 16:1660-1661.
61. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the Polin phenol reagent. J. Biol. Chem. 193:265-275.